Genetic changes clinically relevant in canine osteosarcoma


Veröffentlicht: Oct 21, 2024
Versionen:
2024-10-21 (1)
P Loukopoulos
Abstract

Osteosarcoma (OSA) is a malignant tumour of osteoblasts, forming neoplastic bone and/or osteoid. The cancer is most prevalent in children and canines, although occurring 10 times more frequently in the latter (Fenger et al., 2014). Up to 85% of malignant bone cancers are diagnosed as OSA, characterised by aggressive metastasis and rapid haematogenous dissemination, particularly to the lungs (Nelson and Couto, 2019, Thompson and Dittmer, 2020). These most commonly occur in dogs aged between 7-10 years (Selvarajah et al., 2009). The nature of canine osteosarcoma (CnOSA) gravitates to the appendicular skeleton, with 95% prevalence in dogs over 40kg, and 40% prevalence in dogs under 15kg (Nelson and Couto, 2019). Regardless of the high prevalence of CnOSA, there has been little progression in improving survival rates in the last 50 years (Zapata et al., 2019). This may be a consequence of the spontaneity of the cancer in canines (Davis and Ostrander, 2014). However, recent combined utilisation of genomic/transcriptomic technologies has been of benefit to investigating genetic loci as causes and/or protectors against CnOSA (Davis and Ostrander, 2014). As a result, somatic mutations in the TP53, MYC, CDKN2A/B, PTEN, RUNX2, and DLG2 genes in humans and dogs with osteosarcoma– and KIT and MDM2 in OSA dogs alone have been identified (Zapata et al., 2019). These findings are not only of prognostic importance to the several dog breeds with genetic predispositions to CnOSA (Simpson et al., 2017), but for humans too. This is not purely for better diagnosis of at-risk patients, but for earlier management, and a foundation for novel approaches to treatment targets for OS. Therefore, this literature review aims to identify the genetic changes clinically relevant in dogs with osteosarcoma.

Article Details
  • Rubrik
  • Review Articles
Downloads
Keine Nutzungsdaten vorhanden.
Literaturhinweise
Angstadt AY, Thayanithy V, Subramanian S, Modiano JF, Breen M (2012)
A genome-wide approach to comparative oncology: high-resolution
oligonucleotide aCGH of canine and human osteosarcoma pinpoints
shared microaberrations. Cancer Genet 205:572-587.
Dailey DD, Anfinsen KP, Pfaff LE, Ehrhart EJ, Charles JB, Bønsdorff TB,
Thamm DH, Powers BE, Jonasdottir TJ, Duval DL (2013) HES1, a
target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors. BMC Vet Res 9:130.
Dailey DD, Hess AM, Bouma GJ, Duval DL (2021) MicroRNA expression changes and integrated pathways associated with poor outcome
in canine osteosarcoma. Front in Vet Sci 8:637622.
Davis BW, Ostrander EA (2014) Domestic dogs and cancer research: a
breed-based genomics approach. ILAR J 55:59-68.
Fenger JM, London CA, Kisseberth WC (2014) Canine osteosarcoma:
a naturally occurring disease to inform pediatric oncology. ILAR J
:69-85.
Fenger JM, Roberts RD, Iwenofu OH, Bear MD, Zhang X, Couto JI,
Modiano JF, Kisseberth WC, London CA (2016) MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and
osteosarcoma cell lines. BMC Cancer 16:784
Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA (2011) Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer 11:125.
Gardner HL, Sivaprakasam K, Briones N, Zismann V, Perdigones N,
Drenner K, Facista S, Richholt R, Liang W, Aldrich J, Trent JM,
Shields PG, Robinson N, Johnson J, Lana S, Houghton P, Fenger J,
Lorch G, Janeway KA, London CA, Hendricks WPD (2019) Canine
osteosarcoma genome sequencing identifies recurrent mutations in
DMD and the histone methyltransferase gene SETD2. Commun Biol
:266
Harrison BM, Loukopoulos P (2021) Genomics and transcriptomics in
veterinary oncology. Oncol Lett 21:336
Jubb KVF, Kennedy PC, Palmer N (ed) (2012) Pathology of domestic
animals. 4th ed, Academic Press.
Kirpensteijn J, Kik M, Teske E, Rutteman GR (2008) TP53 gene mutations in canine osteosarcoma. Vet Surg 37:454-460.
Leonardo L, Laura P, Serena BM (2018) miR-1 and miR-133b expression
in canine osteosarcoma. Res Vet Sci 117:133-137.
Loukopoulos P, Thornton JR, Robinson WF (2003) Clinical and pathologic relevance of p53 index in canine osseous tumors. Vet Pathol
:237-48.
Loukopoulos P, Mungall BA, Straw RC, Thornton JR, Robinson WF.
Matrix metalloproteinase-2 and -9 involvement in canine tumors. Vet
Pathol 40:382-94.
Loukopoulos P, O’Brien T, Ghoddusi M, Mungall BA, Robinson WF
(2004). Characterisation of three novel canine osteosarcoma cell
lines producing high levels of matrix metalloproteinases. Res Vet Sci
:131-41.
Loukopoulos P, Rozmanec M, and Sutton, RH (2005) Cytological versus histopathological diagnosis in canine osteosarcoma. Vet Rec 157:
, 2005.
Lopez CM, Yu PY, Zhang X, Yilmaz AS, London CA, Fenger JM (2018)
MiR-34a regulates the invasive capacity of canine osteosarcoma cell
lines. PLoS One 13:e0190086
Nelson RW, Couto CG (2019) Small Animal Internal Medicine. 6th Ed,
Elsevier, Missouri, U.S.
Sagartz JE, Bodley WL, Gamblin RM, Couto CG, Tierney LA, Capen CC
(1996) p53 tumor suppressor protein overexpression in osteogenic
tumors of dogs. Vet Pathol 33:213-221
Selvarajah GT, Kirpensteijn J, van Wolferen ME, Rao NA, Fieten H, Mol
JA (2009) Gene expression profiling of canine osteosarcoma reveals
genes associated with short and long survival times. Mol Cancer 8:72.
Shao YW, Wood GA, Lu J, Tang QL, Liu J, Molyneux S, Chen Y, Fang H,
Adissu H, McKee T, Waterhouse P, Khokha R (2019) Cross-species
genomics identifies DLG2 as a tumor suppressor in osteosarcoma.
Oncogene 38:291-298.
Simpson S, Dunning MD, de Brot S, Grau-Roma L, Mongan NP, Rutland
CS (2017) Comparative review of human and canine osteosarcoma:
morphology, epidemiology, prognosis, treatment and genetics. Acta
Vet Scand 59:71
Thompson KG, Dittmer, KE (2020) Tumors of Bone. In: Tumors in Domestic Animals, 5th Ed, Wiley, John Wiley & Sons Inc: pp356
Zapata I, Moraes LE, Fiala EM, Zaldivar-Lopez S, Couto CG, Rowell JL,
Alvarez CE Z (2019) Risk-modeling of dog osteosarcoma genome
scans shows individuals with mendelian-level polygenic risk are
common. BMC Genomics 20:226
Am häufigsten gelesenen Artikel dieser/dieses Autor/in